NASD · Healthcare · Biotechnology · USA
Editas Medicine Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Editas Medicine develops genomic medicines using CRISPR gene editing technology to treat serious diseases. The company employs a proprietary platform based on CRISPR/Cas9 and CRISPR/Cas12a systems to edit DNA sequences with precision. Its lead candidate targets hyperlipidemia through in vivo gene editing, while pursuing partnerships for cell therapy and out-licensing technology.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Editas Medicine Inc stock.
Overvalued: intrinsic value $0.03 per share, market price $1.83, margin of safety -5958.7% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $1.83 is 5959% above that value.
17 more funds hold it; the full list is part of the paid plan.
126 more in this industry show a wider margin of safety.
EDIT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $1.83 is 5959% above that value.
$0.03 per share (as of the 2026-11-17 close), against a market price of $1.83. That is a margin of safety of -5958.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.